Pharma News

YH-25724 by Boehringer Ingelheim International for Obesity: Likelihood of Approval


GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

YH-25724 overview

YH-25724 is under development for the treatment of non-alcoholic steatohepatitis (NASH), obesity and non-alcoholic fatty liver disease (NAFLD). It is administered through subcutaneous route. It acts by targeting fibroblast growth factor 21 (FGF21) and glucagon like peptide 1 (GLP1) receptors. The drug candidate is developed based on hybrid Fc fusion protein platform technology.

It was also under development for the treatment of type 2 diabetes.

Boehringer Ingelheim International overview

Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

For a complete picture of YH-25724’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 9 October 2023

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.




Source link
#YH25724 #Boehringer #Ingelheim #International #Obesity #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *